Key insights
- Lucid Capital Markets initiated coverage of NextCure (NXTC) with a buy rating and a $25 price target, citing the potential of its ADC pipeline, particularly SIM0505 for cancer treatment. The firm projects significant revenue potential for SIM0505 and LNCB74. While the company is early-stage with a small market cap, its strong cash position provides runway into 2027. The upcoming ASCO 2026 data readout is a key catalyst.
Investing.com - Lucid Capital Markets initiated coverage on NextCure Inc. (NASDAQ:NXTC) with a buy rating and a price target of $25.00, citing the clinical-stage biotechnology company’s antibody-drug conjugate pipeline for cancer treatment. The target represents substantial upside from the current stock price of $9.76, though the company’s modest market capitalization of $35.2 million reflects its early-stage status.
The firm highlighted SIM0505, a CDH6-directed ADC engineered for fast systemic clearance and an improved therapeutic window, as the core focus of the company. NextCure in-licensed the asset from Simcere Zaiming in June 2025 for ex-Greater China rights, with upfront, development, regulatory and sales milestones of up to approximately $745 million, plus tiered royalties up to the double-digits on net sales.
The asset could potentially address patients with platinum-resistant ovarian cancer, non-small cell lung cancer, and renal cell carcinoma. Lucid Capital Markets said it will be looking forward to the imminent ASCO 2026 data readout as a key potential inflection point for shares, with investors expected to focus on response rate, durability, and the safety profile across the dose range.
Based on its forecasts, SIM0505 could generate approximately $1.5 billion in peak non-risk-adjusted ex-China revenues. The company’s second asset, LNCB74, a B7-H4-directed ADC, could also add to the investment thesis on positive data. Notably, the stock has delivered an 82% return over the past year, though shares remain down 31% year-to-date.
The $25 price target is driven by SIM0505 at approximately $18 per share and LNCB74 at approximately $7 per share. With approximately $41.8 million of cash and equivalents, Lucid Capital Markets estimates runway into the first half of 2027. An InvestingPro tip notes the company holds more cash than debt on its balance sheet, with a current ratio of 4.61 indicating strong liquidity. For deeper insights into NXTC’s financial health and additional ProTips, visit InvestingPro.
In other recent news, NextCure Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. announced the start of a dose optimization study for their investigational drug SIM0505 in patients with platinum-resistant ovarian cancer. This study is part of a Phase 1 clinical trial and aims to determine the optimal dosage for future registrational studies. SIM0505 is an antibody drug conjugate that targets Cadherin-6 and includes a topoisomerase 1 inhibitor payload. Additionally, NextCure and Simcere Zaiming plan to present data from this Phase 1 trial at the American Society for Clinical Oncology annual meeting. The presentation will focus on the drug’s potential in treating advanced solid tumors, particularly ovarian cancer resistant to platinum-based treatments. These developments highlight the ongoing efforts by NextCure and Simcere Zaiming to advance their cancer treatment research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.